[go: up one dir, main page]

MX2016008441A - Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano. - Google Patents

Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.

Info

Publication number
MX2016008441A
MX2016008441A MX2016008441A MX2016008441A MX2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A MX 2016008441 A MX2016008441 A MX 2016008441A
Authority
MX
Mexico
Prior art keywords
growth factor
fibroblast growth
xiloglucano
geles
formulation
Prior art date
Application number
MX2016008441A
Other languages
English (en)
Other versions
MX375204B (es
Inventor
Lo Presti Caterina
Bulone Donatella
DISPENZA Clelia
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MX2016008441A publication Critical patent/MX2016008441A/es
Publication of MX375204B publication Critical patent/MX375204B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al campo de las formulaciones farmacéuticas; más en particular, está dirigida a hidrogeles de xiloglucano que comprenden un compuesto de factor de crecimiento de fibroblastos 18 (FGF-18) y a métodos para producción de dicho hidrogeles; los hidrogeles de la invención se pueden usar, una vez formados in situ, para el tratamiento de trastornos de cartílago tales como osteoartritis o lesión de cartílago.
MX2016008441A 2013-12-24 2014-12-23 Formulación de factor de crecimiento de fibroblastos 18 en geles de xiloglucano. MX375204B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199588 2013-12-24
PCT/EP2014/079194 WO2015097233A1 (en) 2013-12-24 2014-12-23 Fgf-18 formulation in xyloglucan gels

Publications (2)

Publication Number Publication Date
MX2016008441A true MX2016008441A (es) 2017-01-11
MX375204B MX375204B (es) 2025-03-06

Family

ID=49882941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008441A MX375204B (es) 2013-12-24 2014-12-23 Formulación de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.

Country Status (16)

Country Link
US (1) US10293051B2 (es)
EP (1) EP3086803B1 (es)
JP (1) JP6791754B2 (es)
KR (2) KR20160102032A (es)
CN (1) CN106029085B (es)
AU (1) AU2014372575B2 (es)
BR (1) BR112016014578B1 (es)
CA (1) CA2934470C (es)
ES (1) ES2865723T3 (es)
IL (1) IL246435B (es)
MX (1) MX375204B (es)
NZ (1) NZ721332A (es)
RU (1) RU2695343C2 (es)
SG (1) SG11201604927RA (es)
WO (1) WO2015097233A1 (es)
ZA (1) ZA201604609B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014372578B2 (en) 2013-12-24 2018-03-01 Ares Trading S.A FGF-18 formulation in alginate/collagen hydrogels
JP6787904B2 (ja) 2015-01-29 2020-11-18 アレス トレーディング ソシエテ アノニム 高度に正に荷電したタンパク質のイムノアッセイ
US11467169B2 (en) 2017-09-29 2022-10-11 Merck Patent Gmbh Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US11513128B2 (en) 2017-09-29 2022-11-29 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
WO2024084807A1 (ja) * 2022-10-19 2024-04-25 学校法人東邦大学 線維芽細胞増殖因子１８の測定方法及び測定用試薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913159B1 (en) * 1996-02-13 2002-09-25 Dainippon Pharmaceutical Co., Ltd. Drug delivery system using galactoxyloglucan
EP1797869A3 (en) * 1999-07-21 2008-07-23 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
US7217294B2 (en) * 2003-08-20 2007-05-15 Histogenics Corp. Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
CN102600066A (zh) * 2012-04-01 2012-07-25 山东喜丰田生态肥业有限公司 一种含有扑热息痛的温度敏感凝胶缓释口服剂
WO2014062538A1 (en) * 2012-10-19 2014-04-24 3M Innovative Properties Company Polysaccharide-containing hydrogels, compositions, articles, and methods
AU2014372578B2 (en) 2013-12-24 2018-03-01 Ares Trading S.A FGF-18 formulation in alginate/collagen hydrogels

Also Published As

Publication number Publication date
CA2934470A1 (en) 2015-07-02
BR112016014578B1 (pt) 2023-01-24
JP6791754B2 (ja) 2020-11-25
RU2016129827A (ru) 2018-01-30
US10293051B2 (en) 2019-05-21
CN106029085A (zh) 2016-10-12
JP2017502043A (ja) 2017-01-19
AU2014372575A1 (en) 2016-07-07
IL246435A0 (en) 2016-08-31
WO2015097233A1 (en) 2015-07-02
KR102622290B1 (ko) 2024-01-05
ES2865723T3 (es) 2021-10-15
RU2016129827A3 (es) 2018-09-03
EP3086803A1 (en) 2016-11-02
CN106029085B (zh) 2020-08-04
KR20220054446A (ko) 2022-05-02
NZ721332A (en) 2022-07-01
ZA201604609B (en) 2022-05-25
EP3086803B1 (en) 2021-02-17
CA2934470C (en) 2023-06-27
IL246435B (en) 2021-03-25
AU2014372575B2 (en) 2020-07-09
MX375204B (es) 2025-03-06
KR20160102032A (ko) 2016-08-26
SG11201604927RA (en) 2016-07-28
BR112016014578A2 (pt) 2017-10-24
US20160317668A1 (en) 2016-11-03
RU2695343C2 (ru) 2019-07-23

Similar Documents

Publication Publication Date Title
MX2016008442A (es) Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EP3318564A3 (en) Bicyclic heterocycles as fgfr inhibitors
MY199220A (en) Heterocyclic compounds as immunomodulators
MX2016008441A (es) Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.
SA518391170B1 (ar) مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201791451A1 (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12013502529A1 (en) Freeze-dried formulations of fgf-18
MX391040B (es) Formulacion de alta concentracion.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
WO2014145485A3 (en) Map kinase modulators and uses thereof
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX2022015456A (es) Composiciones de maca y metodos de uso.
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FG Grant or registration